218 related articles for article (PubMed ID: 32606435)
1. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
3. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of prostate cancer detection including the prostate health index (phi).
Mathieu R; Castelli C; Fardoun T; Peyronnet B; Shariat SF; Bensalah K; Vincendeau S
World J Urol; 2019 Mar; 37(3):481-487. PubMed ID: 29980838
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
Getaneh AM; Heijnsdijk EA; de Koning HJ
Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
13. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
16. Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.
Barnett CL; Tomlins SA; Underwood DJ; Wei JT; Morgan TM; Montie JE; Denton BT
Med Decis Making; 2017 Oct; 37(7):815-826. PubMed ID: 28363265
[TBL] [Abstract][Full Text] [Related]
17. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea.
Shin S; Kim YH; Hwang JS; Lee YJ; Lee SM; Ahn J
Asian Pac J Cancer Prev; 2014; 15(8):3383-9. PubMed ID: 24870726
[TBL] [Abstract][Full Text] [Related]
19. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.
Ito K; Miyakubo M; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
World J Urol; 2013 Apr; 31(2):305-11. PubMed ID: 22903772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
